ANP.AX (Mkap €11 M) DMD P2 Daten im Q4 = MEGA ZOCK (Seite 92)
eröffnet am 25.07.19 12:43:02 von
neuester Beitrag 12.06.24 23:07:36 von
neuester Beitrag 12.06.24 23:07:36 von
Beiträge: 2.055
ID: 1.308.085
ID: 1.308.085
Aufrufe heute: 0
Gesamt: 244.618
Gesamt: 244.618
Aktive User: 0
ISIN: AU0000317281 · WKN: A3E1W6
0,0528
EUR
-5,21 %
-0,0029 EUR
Letzter Kurs 19.06.24 Lang & Schwarz
Neuigkeiten
| TitelBeiträge |
|---|
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6499 | +58,47 | |
| 19,750 | +18,69 | |
| 4,9100 | +13,13 | |
| 0,5801 | +10,50 | |
| 6,5800 | +10,03 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7811 | -20,54 | |
| 0,9500 | -22,76 | |
| 80,22 | -23,42 | |
| 5,0000 | -28,57 | |
| 5,01 | -33,20 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 67.553.820 von f_moll am 22.03.21 15:02:54Das ist falsch. Die Nachricht kam vormittags in Australien. Bei uns findest du die News per Sonntagabend schon auf Finanznachrichten.de
Um genau zu sein kam das announcement 22:29 GMT am 21.03.2021
Um genau zu sein kam das announcement 22:29 GMT am 21.03.2021
Da die Ernennung erst spät kam, konnte der Aktienkurs in Ausstralien nicht
reagieren. Man nimmt an, dass morgen der Kurs bis 25c ansteigt.
Hier der Link dafür
https://hotcopper.com.au/threads/chart.4522924/page-3299?pos…
reagieren. Man nimmt an, dass morgen der Kurs bis 25c ansteigt.
Hier der Link dafür
https://hotcopper.com.au/threads/chart.4522924/page-3299?pos…
Eine Meinung zu der Ernennung der neuen Direktorin aus TopCopper
---------------------------------------------------------------------------------------------
Still smiling at todays ann.
Does anyone think Dr Gittleson would not have asked for access to the full data before agreeing to be NED at a speculative ASX microcap?
She is used to winning at CSL, she wants to be part of a success story.
She would have seen the "special" P2 data that Prof. Voit raved about - in a more discerning way than we can ever imagine.....before making her decision.
Her appointment is definitely one of the catalysts that Wilson mentioned in their report.
The transformation has begun.
-----------------------------------------
übersetzt
---------------------------------------
Immer noch lächelnd bei der heutigen ann.
Glaubt irgendjemand, dass Dr. Gittleson nicht um Zugang zu den vollständigen Daten gebeten hätte, bevor sie zustimmte, NED bei einem spekulativen ASX Microcap zu sein?
Sie ist es gewohnt, bei CSL zu gewinnen, sie will Teil einer Erfolgsgeschichte sein.
Sie hätte die "besonderen" P2-Daten gesehen, von denen Prof. Voit schwärmte - und zwar auf eine anspruchsvollere Weise, als wir uns jemals vorstellen können....., bevor sie ihre Entscheidung traf.
Ihre Ernennung ist definitiv einer der Katalysatoren, die Wilson in seinem Bericht erwähnt.
Die Transformation hat begonnen.
-----------------------------------------------------------------------
Also die neue Direktorin
Dr. Gittleson will ein Teil der Erfolgsgeschichte sein !!!
-----------------------------------------------------------------------
und wir wollen an der Erfolgsgeschichte teilhaben mit steigenden Akktienkurs !!!!!
uns allen viel Erfolg
f_moll
---------------------------------------------------------------------------------------------
Still smiling at todays ann.
Does anyone think Dr Gittleson would not have asked for access to the full data before agreeing to be NED at a speculative ASX microcap?
She is used to winning at CSL, she wants to be part of a success story.
She would have seen the "special" P2 data that Prof. Voit raved about - in a more discerning way than we can ever imagine.....before making her decision.
Her appointment is definitely one of the catalysts that Wilson mentioned in their report.
The transformation has begun.
-----------------------------------------
übersetzt
---------------------------------------
Immer noch lächelnd bei der heutigen ann.
Glaubt irgendjemand, dass Dr. Gittleson nicht um Zugang zu den vollständigen Daten gebeten hätte, bevor sie zustimmte, NED bei einem spekulativen ASX Microcap zu sein?
Sie ist es gewohnt, bei CSL zu gewinnen, sie will Teil einer Erfolgsgeschichte sein.
Sie hätte die "besonderen" P2-Daten gesehen, von denen Prof. Voit schwärmte - und zwar auf eine anspruchsvollere Weise, als wir uns jemals vorstellen können....., bevor sie ihre Entscheidung traf.
Ihre Ernennung ist definitiv einer der Katalysatoren, die Wilson in seinem Bericht erwähnt.
Die Transformation hat begonnen.
-----------------------------------------------------------------------
Also die neue Direktorin
Dr. Gittleson will ein Teil der Erfolgsgeschichte sein !!!
-----------------------------------------------------------------------
und wir wollen an der Erfolgsgeschichte teilhaben mit steigenden Akktienkurs !!!!!
uns allen viel Erfolg
f_moll
Die Nachkäufe während der Schwäche in den letzten Wochen sehen im Moment gut aus.😎
Trading Spotlight
Hier ist Charmaine - Neues Mitglied im Vorstand Antisense
https://hotcopper.com.au/threads/ann-antisense-therapeutics-…
https://hotcopper.com.au/threads/ann-antisense-therapeutics-…
Antwort auf Beitrag Nr.: 67.547.655 von f_moll am 22.03.21 08:31:20Antisense Therapeutics Limited News
View this email in your browser
ASX Announcement
___________________________________________________________________________________
22 March 2021
Antisense Therapeutics appoints new Non-Executive Director
The Board of Directors of Antisense Therapeutics Limited [ASX:ANP| US OTC:ATHJY | FSE:AWY], (the Company) is pleased to announce the appointment of Charmaine Gittleson M.D as a Non-Executive Director of the Company.
Dr Gittleson is a senior executive with extensive international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited (ASX: CSL). During her time at CSL, Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas.
At CSL Dr Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020. Dr Gittleson was Chair of the company’s Global Benefit Risk Committee, overseeing overall product safety which facilitated regulatory approvals in USA, EU, Japan, South America and Asia-Pacific; Chair of CSL’s Bioethics Advisory Forum; and Chair of CSL’s Strategic and Technical Risk Committee, tasked with delivering development programs on time with quality and within budget, achieving five new major global product approvals and launches within a 24-month period, which included a number of rare disease therapies.
Notably in her role as Senior Vice President Clinical Development, Dr Gittleson led all clinical and safety strategic and operational R&D functions (over 350 staff) with teams in USA, Europe, Japan, China and Australia and was responsible for overseeing a large annual clinical development budget and was a key participant in regulatory agency negotiations, due diligence activities, industry meetings and annual analyst briefings. Dr Gittleson has been a scientific speaker at multiple medical conferences and regulatory workshops (FDA and EMA) and a keynote speaker at Women in Pharma & Leadership conferences for Women in ASX200 listed companies 2017, 2018 and 2019.
Dr Gittleson is a qualified medical physician and holds a Bachelor of Science and a Bachelor of Medicine and Surgery both from the University of Witwatersrand and an Australian Medical Council Qualification. Dr Gittleson is a graduate of the Australian Institute of Company Directors and Stanford University’s Company Directors Course.
In welcoming Dr Gittleson to the Board, Antisense Therapeutics Chairman Bob Moses said “Dr Gittleson brings to our Board absolutely ideal clinical development, regulatory and commercialization experience at the perfect time for the Company as we approach launch of our Phase IIb clinical trial of ATL1102 for treatment of Duchenne’s muscular dystrophy. We are extremely pleased to have attracted someone of Charmaine’s caliber. Charmaine will add an immediate, constructive, and very welcome contribution to the Board. In my opinion, Dr Gittleson’s acceptance is an outstanding endorsement of Antisense Therapeutics and its technology development pipeline.”
Dr Gittleson added “I am thrilled to be joining the Antisense Therapeutics Board at this key juncture in the development pathway of ATL1102. My corporate career has been dedicated to working in rare diseases and the communities and being able to continue contributing, now to the Duchenne’s community with a novel and robust scientific approach is inspiring.”
Dr Gittleson’s appointment is effective immediately and will be confirmed with shareholders following the 2021 Annual General Meeting at which time Dr Graham Mitchell, current non-executive director of ANP intends to retire from the Board of Directors and so will not seek re-election.
The Board of Antisense Therapeutics would like to take this opportunity to thank Graham for nearly 20 years of invaluable contribution to the growth and successful stewardship of ANP as it has advanced from drug discovery into late-stage clinical development and is now on the path to drug commercialisation. Graham is expected to continue to support the company in an ongoing consultant capacity.
Dr Mitchell said “It is wonderful to be passing the baton to another CSL executive. I am particularly happy to have contributed to the earlier research and clinical stages of the company’s development, which aligned with my science background. I am pleased that the appointment of Charmaine truly reflects the advanced stage of product development within the Company. The prospects are such that I look forward to having ongoing active interest in assured successful progress of ANP.”
Authorised for release by the Board.
For more information please contact:
Antisense Therapeutics Investment Enquiries
Mark Diamond Gennadi Koutchin
Managing Director & CEO XEC Partners
+61 (0)3 9827 8999 gkoutchin@xecpartners.com.au
www.antisense.com.au 1300 932 037
About Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY| FSE:AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.
View this email in your browser
ASX Announcement
___________________________________________________________________________________
22 March 2021
Antisense Therapeutics appoints new Non-Executive Director
The Board of Directors of Antisense Therapeutics Limited [ASX:ANP| US OTC:ATHJY | FSE:AWY], (the Company) is pleased to announce the appointment of Charmaine Gittleson M.D as a Non-Executive Director of the Company.
Dr Gittleson is a senior executive with extensive international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited (ASX: CSL). During her time at CSL, Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas.
At CSL Dr Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020. Dr Gittleson was Chair of the company’s Global Benefit Risk Committee, overseeing overall product safety which facilitated regulatory approvals in USA, EU, Japan, South America and Asia-Pacific; Chair of CSL’s Bioethics Advisory Forum; and Chair of CSL’s Strategic and Technical Risk Committee, tasked with delivering development programs on time with quality and within budget, achieving five new major global product approvals and launches within a 24-month period, which included a number of rare disease therapies.
Notably in her role as Senior Vice President Clinical Development, Dr Gittleson led all clinical and safety strategic and operational R&D functions (over 350 staff) with teams in USA, Europe, Japan, China and Australia and was responsible for overseeing a large annual clinical development budget and was a key participant in regulatory agency negotiations, due diligence activities, industry meetings and annual analyst briefings. Dr Gittleson has been a scientific speaker at multiple medical conferences and regulatory workshops (FDA and EMA) and a keynote speaker at Women in Pharma & Leadership conferences for Women in ASX200 listed companies 2017, 2018 and 2019.
Dr Gittleson is a qualified medical physician and holds a Bachelor of Science and a Bachelor of Medicine and Surgery both from the University of Witwatersrand and an Australian Medical Council Qualification. Dr Gittleson is a graduate of the Australian Institute of Company Directors and Stanford University’s Company Directors Course.
In welcoming Dr Gittleson to the Board, Antisense Therapeutics Chairman Bob Moses said “Dr Gittleson brings to our Board absolutely ideal clinical development, regulatory and commercialization experience at the perfect time for the Company as we approach launch of our Phase IIb clinical trial of ATL1102 for treatment of Duchenne’s muscular dystrophy. We are extremely pleased to have attracted someone of Charmaine’s caliber. Charmaine will add an immediate, constructive, and very welcome contribution to the Board. In my opinion, Dr Gittleson’s acceptance is an outstanding endorsement of Antisense Therapeutics and its technology development pipeline.”
Dr Gittleson added “I am thrilled to be joining the Antisense Therapeutics Board at this key juncture in the development pathway of ATL1102. My corporate career has been dedicated to working in rare diseases and the communities and being able to continue contributing, now to the Duchenne’s community with a novel and robust scientific approach is inspiring.”
Dr Gittleson’s appointment is effective immediately and will be confirmed with shareholders following the 2021 Annual General Meeting at which time Dr Graham Mitchell, current non-executive director of ANP intends to retire from the Board of Directors and so will not seek re-election.
The Board of Antisense Therapeutics would like to take this opportunity to thank Graham for nearly 20 years of invaluable contribution to the growth and successful stewardship of ANP as it has advanced from drug discovery into late-stage clinical development and is now on the path to drug commercialisation. Graham is expected to continue to support the company in an ongoing consultant capacity.
Dr Mitchell said “It is wonderful to be passing the baton to another CSL executive. I am particularly happy to have contributed to the earlier research and clinical stages of the company’s development, which aligned with my science background. I am pleased that the appointment of Charmaine truly reflects the advanced stage of product development within the Company. The prospects are such that I look forward to having ongoing active interest in assured successful progress of ANP.”
Authorised for release by the Board.
For more information please contact:
Antisense Therapeutics Investment Enquiries
Mark Diamond Gennadi Koutchin
Managing Director & CEO XEC Partners
+61 (0)3 9827 8999 gkoutchin@xecpartners.com.au
www.antisense.com.au 1300 932 037
About Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY| FSE:AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.
Antwort auf Beitrag Nr.: 67.547.373 von ballalo am 22.03.21 08:10:07
in Ausstralien ist es jetzt 18:30
siehe den Link hier wird der Kurs vom 22.3.2021 angezeigt
https://hotcopper.com.au/asx/anp/discussion/
Die Börse war offen - Jetzt ist diese geschlossen
Zitat von ballalo:Zitat von Nantor: https://de.advfn.com/borse/ASX/ANP/kurs
Ist die Börse in Australien jetzt nicht offen. Wenn ich auf den Lknk klicke, sehe ich den Kurs vom Freitag, Börse geschlossen.
in Ausstralien ist es jetzt 18:30
siehe den Link hier wird der Kurs vom 22.3.2021 angezeigt
https://hotcopper.com.au/asx/anp/discussion/
Antwort auf Beitrag Nr.: 67.522.097 von Nantor am 19.03.21 09:04:01
Ist die Börse in Australien jetzt nicht offen. Wenn ich auf den Lknk klicke, sehe ich den Kurs vom Freitag, Börse geschlossen.
Zitat von Nantor: https://de.advfn.com/borse/ASX/ANP/kurs
Ist die Börse in Australien jetzt nicht offen. Wenn ich auf den Lknk klicke, sehe ich den Kurs vom Freitag, Börse geschlossen.
Beitrag eines aufgeregten Forumsmitglied HotCopper
---------------------------------------------------------------------------------------------------
Nach 20 Jahren der Beinahe-Fehlschläge und 60 Millionen plus an Forschungsinvestitionen ist ANP buchstäblich über etwas gestolpert, was vielleicht einer der bedeutendsten Fortschritte in der modernen Entzündungsforschung ist, und das genau zu der Zeit, als der "goldene Kelch" der Gentherapie für DMD auf ganzer Linie versagt... Milliarden von Dollar stehen auf dem Spiel und die Zeit tickt für diese armen Jungs. Alle Augen richten sich jetzt auf einen kleinen australischen Micro-Cap mit herausragenden klinischen PH2-Daten, der Hoffnung bietet, wenn es sonst nichts gibt... niemand hat das kommen sehen... niemand hätte auch nur annähernd die erstaunlichen Studienergebnisse und die aktuellen Umstände vorhersagen können, wo wir vor nur 12 Monaten bei 3 Cent waren. Natürlich ist 1102 nicht die totale Lösung, aber durch die Kombination mit der Gentherapie kann es durchaus der Katalysator sein, um das Blatt zu wenden bei dieser Multi-Milliarden-Dollar-Investition in die Gentherapie-Forschung, die so dringend eine Rettungsleine braucht... Ich bin so aufgeregt, mit Ihnen allen in diesem Raum zu sein, während sich diese Geschichte entfaltet... Die besten Wünsche an diejenigen, mit denen ich diese Reise in den letzten 8-10 Jahren geteilt habe und für Ihre unerschütterliche Unterstützung für dieses Unternehmen, Gott segne die Jungs und hoffe, dass etwas Gutes aus all dem bald kommen wird...
---------------------------------------------------
deer Link dazu
https://hotcopper.com.au/threads/chart.4522924/page-3282?pos…
---------------------------------------------------------------------------------------------------
Nach 20 Jahren der Beinahe-Fehlschläge und 60 Millionen plus an Forschungsinvestitionen ist ANP buchstäblich über etwas gestolpert, was vielleicht einer der bedeutendsten Fortschritte in der modernen Entzündungsforschung ist, und das genau zu der Zeit, als der "goldene Kelch" der Gentherapie für DMD auf ganzer Linie versagt... Milliarden von Dollar stehen auf dem Spiel und die Zeit tickt für diese armen Jungs. Alle Augen richten sich jetzt auf einen kleinen australischen Micro-Cap mit herausragenden klinischen PH2-Daten, der Hoffnung bietet, wenn es sonst nichts gibt... niemand hat das kommen sehen... niemand hätte auch nur annähernd die erstaunlichen Studienergebnisse und die aktuellen Umstände vorhersagen können, wo wir vor nur 12 Monaten bei 3 Cent waren. Natürlich ist 1102 nicht die totale Lösung, aber durch die Kombination mit der Gentherapie kann es durchaus der Katalysator sein, um das Blatt zu wenden bei dieser Multi-Milliarden-Dollar-Investition in die Gentherapie-Forschung, die so dringend eine Rettungsleine braucht... Ich bin so aufgeregt, mit Ihnen allen in diesem Raum zu sein, während sich diese Geschichte entfaltet... Die besten Wünsche an diejenigen, mit denen ich diese Reise in den letzten 8-10 Jahren geteilt habe und für Ihre unerschütterliche Unterstützung für dieses Unternehmen, Gott segne die Jungs und hoffe, dass etwas Gutes aus all dem bald kommen wird...
---------------------------------------------------
deer Link dazu
https://hotcopper.com.au/threads/chart.4522924/page-3282?pos…
Durchsuchen
